Instituto de Oncología de Rosario

Rosario, Santa Fe Province S2000KZE, 2457

1 studies enrolling now · 4 studies all time

What they study most

Advanced or Metastatic Breast Cancer, Cancer of the Prostate, HER2-Positive Primary Breast Cancer, Hormone Sensitive Prostate Cancer, Metastatic Breast Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Prostate Cancer, Residual Invasive Breast Cancer

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment — Running, not enrolling
• A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer — Running, not enrolling